An Act amending the act of April 14, 1972 (P.L.233, No.64), known as The Controlled Substance, Drug, Device and Cosmetic Act, further providing for prohibited acts and penalties.
SB75 is a criminal justice and controlled-substances bill that would amend Pennsylvania’s Controlled Substance, Drug, Device and Cosmetic Act. Based on the caption, the measure would revise the statute’s provisions on prohibited acts and penalties, which typically govern unlawful manufacture, delivery, possession, or related conduct involving controlled substances, drugs, devices, or cosmetics. Because the bill text is not available in the provided material, the precise statutory changes cannot be identified from the record here.
The bill was referred to the Senate Judiciary Committee on January 22, 2025, indicating it was being considered as part of the state’s drug enforcement and sentencing framework. Any enacted changes would likely affect criminal penalties, enforcement authority, and individuals or entities subject to the controlled substances laws, including defendants, law enforcement, prosecutors, and potentially regulated businesses involved in pharmaceuticals or other covered products.
SB75 would amend the Controlled Substance, Drug, Device and Cosmetic Act, specifically the sections addressing prohibited acts and penalties. If enacted, it would alter Pennsylvania law governing drug-related offenses and could change how certain violations are charged or punished. The bill would primarily affect criminal defendants, law enforcement, prosecutors, and any regulated parties covered by the act, but the exact scope of the impact cannot be determined from the materials provided because the bill text is unavailable.
No committee transcript or vote record was provided, so there is no direct evidence of support, opposition, or debate in the available materials. The bill’s referral to Judiciary suggests it was still in the early stages of legislative review. On the face of the caption, the measure appears to be a standard criminal-law amendment rather than a broadly framed policy initiative, but the public or committee sentiment cannot be assessed from the record provided.
The main point of potential contention would be any changes to prohibited acts or penalties under Pennsylvania’s drug laws, since such amendments can affect sentencing severity, enforcement discretion, and the treatment of drug-related offenses. Stakeholders who might disagree include criminal justice reform advocates, prosecutors, law enforcement, defense attorneys, and public health groups, depending on whether the bill increases penalties, narrows offenses, or otherwise changes enforcement standards. Because no transcript or vote data is available, specific objections or supporters cannot be identified.